Product Information
EPCLUSA 400 MG-100 MG TABLET is a brand product labeled by Gilead Sciences, Inc., priced at $865.8921 per EA under NDC 61958220101. Its NADAC has been published 389 times since Feb 22, 2017.
FDA first approved this application on Jun 28, 2016.
Strength
400; 100 mg/1; mg/1
Manufacturer
Gilead Sciences, Inc.NDC
61958220101
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
SOFOSBUVIR; VELPATASVIRApproval Type
New Drug (NDA)
FDA Application
NDA208341FDA Approved
6/28/2016
On Market Since
6/28/2016
Pharmacological Classes
Price Statistics
The NADAC for EPCLUSA 400 MG-100 MG TABLET has been published 389 times since Feb 22, 2017, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $865.8921 per EA |
|---|---|
| All-time high | $869.7970 (Apr 10, 2024) |
| All-time low | $852.5161 (Feb 22, 2017) |
| 52-week high | $867.2160 |
| 52-week low | $864.0412 |
| Median price | $867.7500 |
| Average price | $866.3606 |
| Largest weekly change | +1.0% (Oct 18, 2017) |
| Weeks tracked | 389 |
| Tracking since | Feb 22, 2017 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 68% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Gilead Sciences, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Velpatasvir and Sofosbuvir market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Hepatitis C Virus NS5A Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of EPCLUSA 400 MG-100 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for EPCLUSA 400 MG-100 MG TABLET, manufactured by Gilead Sciences, Inc., is $865.8921 per EA (NDC 61958220101), effective Sep 30, 2026.
How has the price of EPCLUSA 400 MG-100 MG TABLET changed over time?
Over the history we have for it, the NADAC for EPCLUSA 400 MG-100 MG TABLET has held within roughly two percent of its current level. It has been tracked across 389 weekly CMS publications since Feb 22, 2017.
What are the highest and lowest recorded NADAC prices for EPCLUSA 400 MG-100 MG TABLET?
Since Feb 22, 2017, the NADAC for EPCLUSA 400 MG-100 MG TABLET has ranged from a low of $852.5161 (Feb 22, 2017) to a high of $869.7970 (Apr 10, 2024), with a median of $867.7500 per EA.
Are there cheaper alternatives to EPCLUSA 400 MG-100 MG TABLET?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, SOFOSBUVIR-VELPATASVIR 400-100, is $278.0258 per EA — about 68% below EPCLUSA 400 MG-100 MG TABLET.
Who manufactures EPCLUSA 400 MG-100 MG TABLET?
EPCLUSA 400 MG-100 MG TABLET (NDC 61958220101) is labeled by Gilead Sciences, Inc., and CMS classifies it as a brand product.